Table 1.

Studies showing incidence of antibodies to infliximab

	Patient cohort	Incidence of antibodies to infliximab
Baert et al17	125 patients with Crohn's disease	61% after fifth infusion (43% v 75% with or without concomitant immunosuppressants respectively); >40% after first infusion
Farrell et al18	53 patients with Crohn's disease	36% (24% v 63% with or without concomitant immunosuppressants respectively)
Hanauer et al19	233 patients with Crohn's disease at week 54	27% (38%, 11%, 8% respectively for episodic treatment; scheduled (every 8 weeks) dose of 5 mg/kg; scheduled (every 8 weeks) dose of 10 mg/kg
Maini et alw24	428 patients with rheumatoid arthritis treated with methotrexate	8%
Wolbink et alw21	50 patients with rheumatoid arthritis (44 taking concomitant methotrexate)	44%